UK Court Finds Teva's Copaxone Patent Valid In Mylan Row

Law360, New York (July 11, 2012, 1:51 PM EDT) -- The U.K.'s High Court of Justice on Wednesday handed a win to Teva Pharmaceutical Industries Ltd. in its patent fight with Mylan Laboratories Inc.'s Generics (UK) Ltd., finding that Teva’s European patent for its multiple sclerosis drug Copaxone is valid.

Generics UK originally brought the action seeking to revoke European Patent (UK) 762,888 — which covers Teva’s Copaxone — and a declaration that its proposed generic version of the drug wouldn't infringe the '888 patent, according to Teva. 

Teva’s patent for Copaxone is set to expire...
To view the full article, register now.